Epigenetics (“Epi”; “over “ or “above” genetics) is recognized as those systems that control the expression of DNA-coded genes, but do not reside in the base pair sequences of the DNA. Rather, these control mechanisms are based on factors or molecules that bind to specific regions of the DNA (the genome), affecting gene expression. The three most important, and best understood mechanisms, are:
This report an assessment of commercial outlook for each one of these categories. It includes market size and forecast for epigenetics in pharmaceutical and diagnostic applications. Epigenetics constitutes a challenge to the long held paradigm of DNA base pair sequences as the prime determinant of the phenotype. Because of this profound intellectual shift, a vast new area of biological investigation is rapidly unfolding. This presents significant opportunities for understanding disease processes and developing the means of combating them.
The examination of many diseases in a completely new light means there exist a wealth of opportunities to develop new diagnostic and therapeutic approaches. At the same time it means that outdated concepts will have to be revised. This report looks at the science behind epigenetics and deals with opportunities for product development based on epigenetic technologies and the outlook for the future in this exciting area of pharmaceutical technologies. In doing so, the report provides:
The report strives to predict the potential for epigenomics while reminding market-watchers of the challenges and possible limiting factors in this market.
Mabs" and molecular tests are among the growth industries of pharmaceuticals and diagnostics, but they may have competition long-term from an unexpected source.
Epigenetics is a potential game-changer in the clinical therapeutics market and significant in testing as well. It refers to technologies involving changes in genetic material that find their origins in causes other than base pairs alterations in the DNA of the host. Examples of such changes include DNA methylation and histone acetylation, both of which have been known for many years to cause changes in gene expression. This report Epigenetics, Present and Future Applications for Pharmaceuticals and Diagnostics describes the progress that has been made in our understanding of the basic science of epigenomics and considers the practical accomplishments being reported by the private sector.
The study of epigenomics today finds itself at a tuningpoint, with many unanswered questions and a proliferation of opportunities forproducts based on the constant flow of new research findings. This report is essential for pharmaceutical and diagnostic marketers looking to develop future business plans and determine opportunities in a promising field.
PUBLICATION TSUNAMI SURROUNDING EPIGENETICS
As I noted inmy report on Epigenetics, published by Kalorama in 2012, the field is on thecusp of an explosion, which is now taking place. According to an assessment in GeneticEngineering and Biotechnology News (http://www.genengnews.com/gen-articles/en-bloc-analysis-of-b-epigenetic-b-b-publications-b/4704/),publications are proliferating at an exponential rate, particularly in thefield of cancer research. The authors also claim that other epigenetic-baseddisease research areas are expanding rapidly, including cardiovascular,neurological and obesity targeted investigations.
"In the examination of Google hits for “Epigenetics,” the phrases “exciting”, “state of the art”, “cutting edge”, “innovative”, “breakthrough” and other clichés are encountered over and over. These terms are frequently employed to cover up ideas, concepts and scientific discoveries that may NOT be cutting edge or state of the art and may be past their time, or may never have reached their time. For this reason the report will consider which of these technologies have value and may be ripe for exploitation."
Related Reports:The Global Market for Biomarkers (Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers)
Oct 16, 2013 - KLI5136277 - $3,995.00
The World Market for Orphan Drugs (Markets for Oncology, Hematology, Neurology, Endocrine, Metabolic and Other Drugs)
Jun 13, 2013 - KLI5061933 - $4,500.00
Bioinformatics in IVD Testing
Jun 7, 2013 - KLI5060494 - $1,995.00
The World Market for Pain Management Drugs and Devices
May 20, 2013 - KLI5042319 - $3,500.00
The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives
May 8, 2013 - KLI5036103 - $4,500.00
The Next Wave In Cancer Treatment - Kinase Inhibitors
Dec 4, 2012 - KLI4923367 - $2,500.00
Kalorama Vaccine Market Research Report Bundle (Vaccines 2012, What's Next in Vaccines, Vaccine Production Markets)
Oct 18, 2012 - KLI4891982 - $3,995.00
Early Toxicology: Markets and Approaches
Sep 12, 2012 - KLI4873387 - $3,995.00
DNA Sequencing Markets (Next-Generation Systems, Capillary Systems, Consumables, Services)
Sep 7, 2012 - KLI4871738 - $1,995.00
Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016
Aug 3, 2012 - KLI4859780 - $2,500.00
Questions?Contact a research specialist >
Most Popular ResearchWhy Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals World Market for Molecular Diagnostics, 5th. Edition (Infectious Disease, Oncology, Blood Screening, Pre-Natal and Other Areas) Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) White Paper: Bariatric Surgery Trends